New approaches in the treatment of bacterial infections

被引：37

作者：

Bush, K ^{[1
]}

Macielag, M ^{[1
]}

机构：

[1] RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2000年 / 4卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(00)00106-X

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Recently, several new drugs for the treatment of bacterial infections have been developed. Quinupristin/dalfopristin, moxifloxacin and gatifloxacin have been approved throughout the world for clinical use. Levofloxacin has been approved for the treatment of community-acquired pneumonia caused by penicillin-resistant Streptococcus pnuemoniae. The Food and Drug Administration has approved linezolid for clinical use, and new drug applications for gemifloxacin and telithromycin were filed. Other new targets have surfaced in the quest for novel antibacterial agents.

引用

收藏

页码：433 / 439

页数：7

相关论文

共 60 条

[1] A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new 'respiratory quinolones' [J].

Blondeau, JM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :1-11

[2] Effects of genes encoding resistance to streptogramins A and B on the activity of quinupristin-dalfopristin against Enterococcus faecium [J].

Bozdogan, B ;

Leclercq, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (11) :2720-2725

[3] Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic [J].

Breukink, E ;

Wiedemann, I ;

van Kraaij, C ;

Kuipers, OP ;

Sahl, HG ;

de Kruijff, B .

SCIENCE, 1999, 286 (5448) :2361-2364

[4] The lantibiotic nisin, a special case or not? [J].

Breukink, E ;

de Kruijff, B .

BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1999, 1462 (1-2) :223-234

[5] In vitro activity of ABT-773, a new ketolide, against recent clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [J].

Brueggemann, AB ;

Doern, GV ;

Huynh, HK ;

Wingert, EM ;

Rhomberg, PR .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (02) :447-449

[6] Phenotypic distinction in Enterococcus faecium and Enterococcus faecalis strains between susceptibility and resistance to growth-enhancing antibiotics [J].

Butaye, P ;

Devriese, LA ;

Haesebrouck, F .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) :2569-2570

[7] In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic [J].

Candiani, G ;

Abbondi, M ;

Borgonovi, M ;

Romanò, G ;

Parenti, F .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :179-192

[8] Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].

Chen, DK ;

McGeer, A ;

de Azavedo, JC ;

Low, DE .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239

[9] Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor [J].

Chen, DZ ;

Patel, DV ;

Hackbarth, CJ ;

Wang, W ;

Dreyer, G ;

Young, DC ;

Margolis, PS ;

Wu, C ;

Ni, ZJ ;

Trias, J ;

White, RJ ;

Yuan, ZY .

BIOCHEMISTRY, 2000, 39 (06) :1256-1262

[10] Carbohydroxamido-oxazolidines: Antibacterial agents that target lipid A biosynthesis [J].

Chen, MH ;

Steiner, MG ;

de Laszlo, SE ;

Patchett, AA ;

Anderson, MS ;

Hyland, SA ;

Onishi, HR ;

Silver, LL ;

Raetz, CRH .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (03) :313-318

← 1 2 3 4 5 6 →